ThisiscontentfromClinicalKey
Sign up for your free ClinicalKey trial today! Your first step in getting the right answers when you need them. ClinicalKey is a clinical knowledge solution designed to help healthcare professionals and students find the right answers by providing in-depth, evidence-based knowledge – all from one resource.
Mild to moderate disease
Severe disease
Relapse prevention
Esketamine nasal spray—the first N-methyl-D-aspartate receptor antagonist to receive FDA approval for major depression—can be used as an adjunct to an oral antidepressant for treatment-resistant depression (those whose condition has failed to respond to 2 or more standard antidepressant treatments)
Music therapy
Acupuncture c123
Exercise c124